The Lancet publication provides independent peer-reviewed validation of the BOND-003 data, which may increase the probability of FDA approval for cretostimogene in BCG-unresponsive NMIBC. Traders should monitor for the FDA decision date and any pre-submission meeting outcomes; a positive approval would be transformative for this single-asset company with a $6.1B market cap.
Price Chart
Executive Summary
CG Oncology published Phase 3 BOND-003 Cohort C results for cretostimogene in BCG-unresponsive NMIBC in The Lancet Oncology, showing a 75.5% complete response rate, median duration of response of 27.9 months, and no Grade 3+ treatment-related adverse events. The publication validates the clinical data ahead of a potential FDA decision, reinforcing the drug's profile as a potential bladder-sparing therapy in a high-need setting with no approved standard of care alternatives beyond cystectomy.
Key Facts
- Phase 3 BOND-003 Cohort C met its primary endpoint with statistical significance; 75.5% of patients achieved complete response at any time.
- Median duration of response was at least 27.9 months and is ongoing; 64.2% and 60.1% maintained response at 12 and 24 months, respectively.
- No Grade 3 or greater treatment-related adverse events, treatment-related discontinuations, or deaths reported.
- 96.6% of patients were free from progression to muscle-invasive bladder cancer at 48 and 96 weeks.
- Cretostimogene has FDA Fast Track and Breakthrough Therapy designations; BOND-003 enrolled 112 patients globally.
Financial Impact
No financial figures provided in the press release; CG Oncology is a late-stage clinical biopharmaceutical company with no approved products or disclosed revenue.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) on safety/efficacy or CMC grounds, which would be severely negative for a single-asset biotech.
- Competing bladder-sparing therapies (e.g., intravesical gemcitabine-docetaxel, pembrolizumab) may limit commercial uptake even if approved.
- Forward-looking statements caution that interim results are not necessarily indicative of final outcomes; regulatory review timelines are uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3333936 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Aug 6, 2026 8w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Jul 27, 2026 9w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | $67.38 (−7.22%) |
Jul 17, 2026 11w ago | Insider Cluster | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | $67.38 (−6.22%) |
Jul 16, 2026 11w ago | Court Ruling | $69.50 $74.71 | ▲ +7.50% | ▲ +3.88% | $67.38 (−3.05%) |
Jun 24, 2026 14w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | $67.38 (−7.50%) |
Jun 22, 2026 14w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | $67.38 (+2.51%) |
Jun 12, 2026 16w ago | Institutional Cluster | $59.56 $75.24 | ▲ +26.33% | ▲ +24.55% | $67.38 (+13.13%) |
May 26, 2026 18w ago | 8-K | $61.89 $70.25 | ▲ +13.50% | ▲ +15.45% | $67.38 (+8.87%) |
May 15, 2026 20w ago | Press Release | $66.93 $59.56 | ▼ −11.01% | ▼ −13.13% | $67.38 (+0.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access